uniQure (QURE) Stock: Falls 3% Despite FDA Priority Review for Huntington’s Disease Gene Therapy

TLDR QURE stock falls 2.98% to $24.09 despite FDA Priority Review for AMT-130. FDA sets May 1, 2027, as the target decision date for uniQure’s gene therapy. uniQure plans to begin screening 200 patients for its confirmatory trial by year-end. AMT-130 targets Huntington’s disease through uniQure’s proprietary gene-silencing platform. QURE shares break below $24.83 support [...]

The post uniQure (QURE) Stock: Falls 3% Despite FDA Priority Review for Huntington’s Disease Gene Therapy appeared first on Blockonomi.